| 专题 |
|
|
|
|
| 在医疗保健领域开发和使用生物标记物的政策性问题 |
| Rachael Ritchie, Marie-Ange Baucher |
| 经济合作与发展组织 |
|
| Policy Issues for the Development and Use of Biomarkers in Health |
| Rachael Ritchie, Marie-Ange Baucher |
| Organisation for Economic Co-operation and Development |
[1] OECD, OECD Health Data 2010, Paris.
[2] World Health Organisation. Preventing Chronic Diseases: a Vital Investment: WHO Global Report, 2005.
[3] Hempel W, Sziraczky G, Swalm L, et, al. Biomarkers: Impact on Biomedical Research and Health Care: Case Reports, OECD Science, Technology and Industry Analytical Paper, Directorate for Science, Technology and Industry, OECD, Paris, 2008.
[4] OECD. Pharmacogenetics: Opportunities and Challenges for Health Innovation, OECD, Paris, 2009b.
[5] Claudio JO, Stewart AK. Advances in Myeloma Genetics and Prospects for Pharmacogenomic Testing in Multiple Myeloma, American Journal of Pharmacogenomics, 2005, 5: 35-43.
[6] McLean LA, Gathmann I, Capdeveile R, et al. Pharmacogenomic Analysis of Cytogenetic Response in Chronic Myeloid Leukemia Patients Treated with Imatinib, Clinical Cancer Research, 2004, 10: 155-165.
[7] Lusky K Wins, Worries on Reimbursement Battlefields, College of American Pathologists, August, 2008.
[8] Genomic Health, Inc. Company Strategy, SWOT Analysis and 5-Year Adjusted Financials, Data Monitor, June, 2006.
[9] Hamilton DP. Genentech's Profit Jumps 64 Percent on Strong Cancer-Drug Sales, Wall Street Journal, January 11, 2006.
[10] Personalized Medicine Coalition. The case for Personalized Medicine, Personalized Medicine Coalition, 2009.
[11] Issa AM. Personalized Medicine and the Practice of Medicine in the 21st Century, McGill Journal of Medicine, 2007, 10(1):53-57.
[12] Epstein RS, Toyer TP, Aubert RE, et al. Warfarin Genotyping Reduces Hospitalisation Rates: Results from the MM-WES (Medco-Mayo Effectiveness Study), Journal of the American College of Cardiology, 2010, 55(25):2804-2812.
[13] Editorial. Vioxx: an unequal partnership between safety and efficacy, The Lancet, 2004, 364 (9442): 1287-1288.
[14] Rubin R. How Did Vioxx Debacle Happen, USA Today, October 12, 2004.
[15] Di Masi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. Journal of Health Economics, 2003, 22:151-185.
[16] Wimo A, Prince M. World Alzheimer Report, Alzheimer's Disease International, Alzheimer's Disease International, 21 September 2010.
[17] OECD. Collaborative Mechanisms for Intellectual Property Management in the Life Sciences, OECD, Paris, 2011.
[18] Centers for Disease Control and Prevention (n.d.). ACCE Model Process for Evaluating Genetic Tests, www.cdc.gov/genomics/gtesting/ACCE/index.htm.
[19] OECD. Health Technologies and Decision Making, OECD, Paris, 2005.
[20] OECD. Guidelines on Human Biobank and Genetic Research Databases, OECD, Paris, 2009a.
[21] Novelli G. Genetic tests and genomic biomarkers: regulation, qualification and validation. Clinical Cases, 2008, 5:140-154.
[22] Personalised Medicine Coalition. The Adverse Impact of the US Reimbursement System on the Development and Adoption of Personalised Medicine Diagnostics, Personalised Medicine Coalition, 2010.
[23] Health Advances. The reimbursement Landscape for novel diagnostics, 2010. http://www.bio.org/healthcare/personalized/Health_Advances&BIO_Novel_Diagnostics_Reimburs_20110103.pdf.
[24] Schmid EF, Smith DA. Is declining innovation in the pharmaceutical industry a myth? Drug Discovery Today, 2005, 10: 1031-1039.
[25] Peck RW. Driving earlier clinical attrition: if you want to find the needle, burn down the haystack. Considerations for biomarker development. Drug Discovery Today, 2007, 12:289-294.
[26] Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase Ⅲ, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). Clin Oncol. 2011, 20;29(21):2866-2874.
[27] Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med, 2009, 3;361(10):947-957. |
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
